entertainment -WSS

entertainment

author：knowledge 2025-08-19 15:02:00 - browse：11

Red blood cells flow in an artery biotech — coverage from STAT — Adobe

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients.

Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen Pharmaceuticals.

The treatment, injected monthly, also reduced the risk of major bleeding events by 74% and gastrointestinal bleeding by 93%, according to Phase 2 results presented here Sunday at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

entertainment

WSS

New clues to why women have higher risk of autoimmune disorders

Biogen walks away from Aduhelm, years after polarizing approval

Syphilis numbers in the United States reach record heights

Readout Newsletter: Merck, J&J, and long Covid

Zyn nicotine pouches become unlikely player in latest culture war

Elizabeth Holmes banned from government health programs

focus

entertainment

explore

Novavax promises a turnaround & Lilly roils the obesity market

The tragedy of Johnson & Johnson’s Covid vaccine

Moonlake's readout produced a cash windfall. Risks remain

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The surgeon had a dilemma only a Nazi medical text could resolve

Virginia high school admissions case could be legal follow

How generative AI ratchets up security threats for health systems

How to save PrEP access — and even expand it

New brain studies show LSD's effects on the brain in full color

entertainment

Elizabeth Holmes banned from government health programs

Why you shouldn’t ask, “What country has the best health care?”

Medicare Advantage insurers face 0.2% cut to 2025 payments

How digital therapeutics firms are pivoting after Pear's bankruptcy

Eli Lilly, Pfizer, and others want in on the online prescription market

Prior authorization will have to move faster under new Biden rule

focus

Wikipedia

entertainment

leisure time